Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes BioPharma DiveThe findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes.Clinical DataMetabolic & GLP-1Read full story pharminent April 16, 2026 (Last updated: April 16, 2026) BioPharma Dive The findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Lilly debuts more Foundayo data as FDA requests post-marketing trialsNext: FDA moves toward easing restrictions on certain peptides Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
